This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de ResApp Health

Salud financiera controles de criterios 3/6

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$2.29m
Patrimonio	AU$689.56k
Total pasivo	AU$5.13m
Activos totales	AU$5.82m

Actualizaciones recientes sobre salud financiera

Recent updates

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Dec 31

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Aug 26

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

May 08

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

Feb 25

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

Dec 23

Análisis de la situación financiera

Pasivos a corto plazo: RAP's short term assets (A$4.1M) do not cover its short term liabilities (A$4.8M).

Pasivo a largo plazo: RAP's short term assets (A$4.1M) exceed its long term liabilities (A$345.7K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RAP is debt free.

Reducción de la deuda: RAP had no debt 5 years ago.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RAP has less than a year of cash runway based on its current free cash flow.

Pronóstico de cash runway: RAP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.6% each year

This company listing is no longer active

Salud financiera de hoja de balance de ResApp Health

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

Recent updates

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited (ASX:RAP).

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.009 loss in FY 2021)

ResApp Health Limited to Report Q4, 2022 Results on Jul 27, 2022

ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx

ResApp Health Limited Announces Results from Data Confirmation Study

No independent directors

No independent directors

ResApp Health Limited to Report Q3, 2022 Results on Apr 26, 2022

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ResApp Health Limited Completes Recruitment in its U.S. Covid-19 Clinical Study

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

ResApp Receives Regulatory Approvals for Cough Counter

ResApp Health Limited Completes COVID-19 Study Recruitment in India

ResApp Health Limited Receives Advanced and Overseas R&D Finding

ResApp Health Limited Receives Regulatory Approval in Indonesia

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Medgate Extends European ResAppDx Trial

Forecast breakeven moved forward to 2021

ResApp Health Limited Reports Recruited the First Participant in Its US-Based Clinical Study to Explore the Relationship Between Cough and SARS-Cov2 Infection

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

ResApp to Progress Clinical Study to Develop Covid-19 Smartphone-Based Screening Test

Medgate AG Commences ResApp Health Limited 's European ResAppDx Trial

Resapp Health Limited Achieves CE Mark for Wearable Device

ResApp Health Limited Provides an Update on its Two-Year, Non-Exclusive Software Licencing Agreement with Workplace Medicine Australia Ltd

ResApp Health Limited Announces Resignation of Stephen Hewitt-Dutton as Joint Company Secretary

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited Strengthens Patent Position in Europe

ResApp Health Limited to Report Q2, 2021 Results on Jan 29, 2021

Resapp Health Limited Appoints Mike Connell as Vice President, Commercial

ResApp Health Limited Launches SleepCheck

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

ResApp Health Limited Releases Version 2.3 of its ResAppDx Smartphone Application

ResApp Health Limited Appoints Stephen Hewitt-Dutton as Joint Company Secretary

ResApp Health Limited Signs Non-Exclusive, Two-Year Software Licensing Agreement with Workplace Medicine Australia Ltd

Medgate to Pilot ResAppDx for Telehealth Across Europe

ResApp Health Limited to Report Q1, 2021 Results on Oct 30, 2020

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited to Report Q4, 2020 Results on Jul 29, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera